Amarin Corp Plc (AMRN)

[ziploc_1]

North..PBM'S (pharmacy benefit managers) are well aware that generic IPE's are infringing on Amarin's CVD patent for Vascepa...yet they provide monetary inducements for pharmacies to dispense generic V, sometimes even if an RX for Vascepa is written as a DAW(dispense as written)...In your opinion, is it practical for Amarin initiate an infringement suit against a PBM?

Rather than have Amarin execute a buy back of 50 million shares, I would prefer to have Amarin spend its cash by suing the PBM, which just eliminated Amarin from its inventory of covered meds...a suit which would claim infringement of Amarin's Vascepa patents for CVD.

At least, that strategy would have a chance of returning cash to Amarin...in addition to sending a signal to other infringers to desist from their own infringing.